Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07112378 · ClinicalTrials.gov registry record · Phase 3

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

A Phase 3 study of Eosinophilic Esophagitis (EoE), sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
20
Enrollment target
6
Study locations

NCT07112378 is a Phase 3 study of Eosinophilic Esophagitis (EoE) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 20 participants, below the 124-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07112378, a Phase 3 study of Eosinophilic Esophagitis (EoE), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
20 participants
Enrollment target
6
Study locations

Study Summary

This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions Studied

Eosinophilic Esophagitis (EoE)

Interventions

  • DRUG dupilumab

Study Locations (6)

Arizona

  • Phoenix Childrens Hospital - Phoenix

Colorado

  • Children's Hospital Colorado - Aurora

Georgia

  • GI Care for Kids LLC - Atlanta

New York

  • Weill Cornell Medicine - New York

North Carolina

  • University of North Carolina, Bioinformatics Building - Chapel Hill

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-11-10
Est. Completion 2028-10-09
Phase Phase 3

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07112378

The ClinicalTrials.gov registry entry for NCT07112378 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 10 other Eosinophilic Esophagitis (EoE) trials with a reported enrollment target (84% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Eosinophilic Esophagitis (EoE) appearing as the primary indexed condition, and to 1 intervention - of which dupilumab is the first listed.

NCT07112378 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT07112378 about?

NCT07112378 is a clinical study titled "A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis". This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and...

What is the current status of trial NCT07112378?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2025-11-10. Estimated completion is 2028-10-09.

What conditions does trial NCT07112378 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis (EoE).

What interventions are being tested in trial NCT07112378?

The interventions under investigation include: dupilumab (DRUG).

Who is sponsoring clinical trial NCT07112378?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07112378 being conducted?

This trial has 6 study locations across Arizona, Colorado, Georgia, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Eosinophilic Esophagitis (EoE)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Eosinophilic Esophagitis (EoE)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.